Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders

Psychopharmacology
Sergi Ferré

Abstract

The psychostimulant properties of caffeine are reviewed and compared with those of prototypical psychostimulants able to cause substance use disorders (SUD). Caffeine produces psychomotor-activating, reinforcing, and arousing effects, which depend on its ability to disinhibit the brake that endogenous adenosine imposes on the ascending dopamine and arousal systems. A model that considers the striatal adenosine A2A-dopamine D2 receptor heteromer as a key modulator of dopamine-dependent striatal functions (reward-oriented behavior and learning of stimulus-reward and reward-response associations) is introduced, which should explain most of the psychomotor and reinforcing effects of caffeine. The model can explain the caffeine-induced rotational behavior in rats with unilateral striatal dopamine denervation and the ability of caffeine to reverse the adipsic-aphagic syndrome in dopamine-deficient rodents. The model can also explain the weaker reinforcing effects and low abuse liability of caffeine, compared with prototypical psychostimulants. Finally, the model can explain the actual major societal dangers of caffeine: the ability of caffeine to potentiate the addictive and toxic effects of drugs of abuse, with the particularly alar...Continue Reading

References

Sep 1, 1975·The Journal of Pharmacy and Pharmacology·N E Andén, D M Jackson
Mar 1, 1977·Pharmacology, Biochemistry, and Behavior·M D Schechter
Dec 1, 1992·Clinical Pediatrics·A Leviton
Dec 1, 1992·Neuroscience·S FerréB B Fredholm
Sep 16, 1991·Neuroscience Letters·S FerréK Fuxe
Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S FerreK Fuxe
Mar 1, 1991·Pharmacology, Biochemistry, and Behavior·N T BrockwellR J Beninger
May 1, 1990·Pharmacology, Biochemistry, and Behavior·D V GauvinF A Holloway
Jul 1, 1987·Neuroscience·B S StarrI C Kilpatrick
Nov 1, 1988·Pharmacology, Biochemistry, and Behavior·E S SteigerwaldM H O'Regan
Feb 1, 1988·Pharmacology, Biochemistry, and Behavior·R R Griffiths, P P Woodson
Feb 1, 1988·Pharmacology, Biochemistry, and Behavior·S G Holtzman, I B Finn
Mar 1, 1986·Pharmacology, Biochemistry, and Behavior·A L MisraR B Pontani
Jan 1, 1971·Acta Physiologica Scandinavica. Supplementum·U Ungerstedt
Jan 1, 1971·Acta Physiologica Scandinavica. Supplementum·U Ungerstedt
Jan 1, 1971·Acta Physiologica Scandinavica. Supplementum·U Ungerstedt
Oct 29, 1971·Science·J F MarshallP Teitelbaum
Mar 1, 1967·Psychological Review·S E Glickman, B B Schiff
Mar 1, 1984·Pharmacology, Biochemistry, and Behavior·B C White, G E Keller
Oct 1, 1980·Journal of Comparative and Physiological Psychology·J F MarshallS Sawyer
Jan 1, 1993·Pharmacology, Biochemistry, and Behavior·O NikodijevićJ W Daly
May 1, 1994·Pharmacology, Biochemistry, and Behavior·C M WorleyS Schenk
May 2, 1994·European Journal of Pharmacology·T KandaJ Nakamura
Mar 1, 1996·Trends in Pharmacological Sciences·K A JacobsonB B Fredholm

❮ Previous
Next ❯

Citations

Oct 30, 2016·Neuroscience and Biobehavioral Reviews·Tom M McLellanHarris R Lieberman
Oct 12, 2016·Current Psychiatry Reports·Fleur HarrisonHenry Brodaty
May 20, 2017·Nutritional Neuroscience·Inés Sánchez-SelleroAndrés Soto-Varela
Nov 12, 2017·Journal of Basic and Clinical Physiology and Pharmacology·Daniel Matovu, Paul E Alele
Jan 24, 2018·Frontiers in Neuroscience·Sergi FerréDiego García-Borreguero
Jan 30, 2018·Frontiers in Pharmacology·Inmaculada Ballesteros-YáñezStefania Gessi
Oct 4, 2017·Expert Review of Neurotherapeutics·Thomas Müller
Jun 20, 2017·Journal of Psychopharmacology·Lilani J ArulkadachamMathew Ling
Jul 24, 2018·Behavioural Pharmacology·Natalia SchwarzkopfPablo Torterolo
Jun 22, 2018·Behavioural Pharmacology·Daniele NeriMaurizio Porfiri
Nov 6, 2018·Psychopharmacology·Nicholas S HaynesRyan K Bachtell
Aug 2, 2019·Journal of Basic and Clinical Physiology and Pharmacology·Rohit M SaneSanjana N Subhedar
Jun 20, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Osama A AbulseoudElliot Stein
May 23, 2020·Scientific Reports·Carlos SanchisJuan Lupiáñez
Sep 29, 2020·Journal of Cognitive Neuroscience·Berry van den BergMonicque M Lorist
May 26, 2018·Molecular Neurobiology·Marla Rivera-OliverManuel Díaz-Ríos
Jul 18, 2018·Proceedings of the National Academy of Sciences of the United States of America·Eva-Maria ElmenhorstDaniel Aeschbach
Oct 20, 2018·Naunyn-Schmiedeberg's Archives of Pharmacology·Max Kenedy Felix Dos SantosBruno Lobão-Soares
Feb 20, 2019·Journal of the International Society of Sports Nutrition·Michal WilkAdam Zajac
Dec 28, 2019·International Journal of Environmental Research and Public Health·Supa Pengpid, Karl Peltzer
May 22, 2020·Journal of Psychopharmacology·Nicolas KoranyiKlaus Rothermund
Oct 11, 2017·Frontiers in Pharmacology·Geoffrey Burnstock
Jul 6, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brenda M GannonGregory T Collins
Jan 7, 2020·Annual Review of Psychology·Roy A Wise, Mykel A Robble
Mar 18, 2020·Journal of Caffeine and Adenosine Research·Mary M SweeneyRoland R Griffiths
Oct 25, 2016·Journal of Strength and Conditioning Research·Jacob J MorseMoh H Malek
Jan 25, 2020·BMC Biology·Attila KöfalviSergi Ferré
Feb 15, 2020·Toxicology Research·M MartinezF E Martinez
Oct 6, 2020·Frontiers in Cell and Developmental Biology·Vikki HoughtonSandrine Thuret
Jan 26, 2021·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Alfgeir L KristjanssonInga Dora Sigfusdottir

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.